New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2013
07:06 EDTVICLVical initiates Phase 1/2 trial of Vaxfectin-formulated therapeutic vaccine
Vical announced the initiation of its Phase 1/2 trial of the company's Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2, or HSV-2, a cause of genital herpes, in approximately 156 subjects. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy in otherwise healthy HSV-2- infected patients aged 18 to 50 years at six key U.S. clinical sites.
News For VICL From The Last 14 Days
Check below for free stories on VICL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for VICL

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use